“…This finding provides additional evidence that elevated BRG1 expression, not BRG1 mutation, is a marker for poor prognosis in an increasing number of cancer types. Prior work has demonstrated that high BRG1 mRNA expression inversely correlates with patient survival in breast cancer (27,28,39), colorectal cancer (62,63), and neuroblastoma (29). In addition, BRG1 is required for various aspects of cancer cell survival, proliferation, and function in HeLa cells (64), leukemia cells (65,66), breast cancer (33,43), hepatocarcinoma (67), colorectal cancer (68), neuroblastoma (29), melanoma (30,69,70), and certain medullablastoma tumors (71).…”